Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer. Connors C, Valente SA, ElSherif A, Escobar P, et al. Ann Surg Oncol 2024 Oct 22. doi: 10.1245/s10434-024-16390.

Read + Share

Amedeo Smart

Independent Medical Education

Connors C, Valente SA, ElSherif A, Escobar P, et al. Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer. Ann Surg Oncol 2024 Oct 22. doi: 10.1245/s10434-024-16390.
PMID: 39436619